Abstract
Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / administration & dosage*
-
Biopsy, Needle
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Follow-Up Studies
-
Gastroscopy / methods
-
Helicobacter Infections / diagnosis
-
Helicobacter pylori / isolation & purification
-
Humans
-
Immunohistochemistry
-
Lymphoma, B-Cell, Marginal Zone / drug therapy*
-
Lymphoma, B-Cell, Marginal Zone / pathology*
-
Male
-
Neoplasm Staging
-
Rituximab
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology*
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab